Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

[Image: see text] Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG le...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:ACS Med Chem Lett
Main Authors: Popovici-Muller, Janeta, Lemieux, René M., Artin, Erin, Saunders, Jeffrey O., Salituro, Francesco G., Travins, Jeremy, Cianchetta, Giovanni, Cai, Zhenwei, Zhou, Ding, Cui, Dawei, Chen, Ping, Straley, Kimberly, Tobin, Erica, Wang, Fang, David, Muriel D., Penard-Lacronique, Virginie, Quivoron, Cyril, Saada, Véronique, de Botton, Stéphane, Gross, Stefan, Dang, Lenny, Yang, Hua, Utley, Luke, Chen, Yue, Kim, Hyeryun, Jin, Shengfang, Gu, Zhiwei, Yao, Gui, Luo, Zhiyong, Lv, Xiaobing, Fang, Cheng, Yan, Liping, Olaharski, Andrew, Silverman, Lee, Biller, Scott, Su, Shin-San M., Yen, Katharine
פורמט: Artigo
שפה:Inglês
יצא לאור: American Chemical Society 2018
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5900343/
https://ncbi.nlm.nih.gov/pubmed/29670690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.7b00421
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים